Product Pipeline

PTG-100: α4β7 Integrin Specific Oral Peptide Antagonist for IBD

PTG-200: A First-in-Class IL-23 Oral Peptide Receptor Antagonist for Treatment of IBD

PTG-300: An Injectable Hepcidin Mimetic to Treat Iron Overload Diseases

Latest News

February 17, 2016

Protagonist Therapeutics Names Thomas P. O’Neil Chief Financial Officer read more

January 8, 2016

Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100 read more

October 20, 2015

Two Poster Presentations on Oral Peptides by Protagonist Therapeutics Accepted for the Upcoming 2015 Advances in IBD – Crohn’s & Colitis Foundation’s Clinical & Research Conference read more

Upcoming Events

April 4-6, 2016

BIO-Europe Spring
Stockholm, Sweden

April 19-21, 2016

Cambridge Healthcare Institute’s Eleventh Annual Drug Discovery Chemistry
San Diego, CA